Agile Therapeutics (STU:0AL) FCF Margin % : 4.77% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Agile Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Agile Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was €0.16 Mil. Agile Therapeutics's Revenue for the three months ended in Dec. 2023 was €3.31 Mil. Therefore, Agile Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 4.77%.

As of today, Agile Therapeutics's current FCF Yield % is -363.73%.

The historical rank and industry rank for Agile Therapeutics's FCF Margin % or its related term are showing as below:

STU:0AL' s FCF Margin % Range Over the Past 10 Years
Min: -6363.68 Med: -963.98 Max: -48.65
Current: -48.65

During the past 12 years, the highest FCF Margin % of Agile Therapeutics was -48.65%. The lowest was -6363.68%. And the median was -963.98%.

STU:0AL's FCF Margin % is ranked worse than
84.31% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.675 vs STU:0AL: -48.65

Agile Therapeutics FCF Margin % Historical Data

The historical data trend for Agile Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics FCF Margin % Chart

Agile Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-6,360.39

-1,596.64

-331.52

-48.88

Agile Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-39.02	-41.84	-154.81	5.48	4.77

Competitive Comparison of Agile Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agile Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's FCF Margin % falls into.

Agile Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Agile Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.782	/	17.967
	=	-48.88 %

Agile Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0.158	/	3.314
	=	4.77 %

Agile Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Agile Therapeutics (STU:0AL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (STU:0AL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AGRX:USA

Address

500 College Road East, Suite 310, Princeton, NJ, USA, 08540

Website

https://www.agiletherapeutics.com

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.

Agile Therapeutics (STU:0AL) Headlines

No Headlines